Novartis gains full FDA nod for Fabhalta in kidney disorder IgAN
With two approved medicines to treat primary immunoglobulin A nephropathy (IgAN) and a third therapy in phase 3…
Can Novartis’ Fabhalta Strengthen Its Nephrology Franchise?
Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline…
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of…
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
– Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta® (iptacopan) in IgA…
Novartis Shares Bolstered by Kidney Disease Therapy Milestone
Novartis’s Fabhalta shows 49.3% slower kidney decline in IgA nephropathy trial, securing FDA Priority Review and bolstering its…